- Home
- NPCE vs PEPG Comparison
NPCE vs PEPG Comparison
Compare NPCE & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- PEPG
- Stock Information
- Founded
- NPCE 1997
- PEPG 2018
- Country
- NPCE United States
- PEPG United States
- Employees
- NPCE N/A
- PEPG N/A
- Industry
- NPCE Medical Specialities
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- PEPG Health Care
- Exchange
- NPCE Nasdaq
- PEPG Nasdaq
- Market Cap
- NPCE 217.5M
- PEPG 250.3M
- IPO Year
- NPCE 2021
- PEPG 2022
- Fundamental
- Price
- NPCE $8.98
- PEPG $4.12
- Analyst Decision
- NPCE Buy
- PEPG Strong Buy
- Analyst Count
- NPCE 7
- PEPG 2
- Target Price
- NPCE $15.71
- PEPG $19.00
- AVG Volume (30 Days)
- NPCE 120.5K
- PEPG 128.6K
- Earning Date
- NPCE 11-12-2024
- PEPG 11-07-2024
- Dividend Yield
- NPCE N/A
- PEPG N/A
- EPS Growth
- NPCE N/A
- PEPG N/A
- EPS
- NPCE N/A
- PEPG N/A
- Revenue
- NPCE $76,452,000.00
- PEPG N/A
- Revenue This Year
- NPCE $20.21
- PEPG N/A
- Revenue Next Year
- NPCE $15.04
- PEPG N/A
- P/E Ratio
- NPCE N/A
- PEPG N/A
- Revenue Growth
- NPCE 27.00
- PEPG N/A
- 52 Week Low
- NPCE $5.45
- PEPG $3.81
- 52 Week High
- NPCE $18.15
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- NPCE 66.14
- PEPG 17.26
- Support Level
- NPCE $6.63
- PEPG $4.36
- Resistance Level
- NPCE $10.42
- PEPG $5.01
- Average True Range (ATR)
- NPCE 0.83
- PEPG 0.59
- MACD
- NPCE 0.30
- PEPG -0.23
- Stochastic Oscillator
- NPCE 67.20
- PEPG 3.31
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.